Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Marc

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Presse Medicale (Paris, France : 1983)|August 1, 2002
[Sexual abuse and chemical submission, a present-day problem]Pascal Burnat, Carine Garcia, Bernard Marc, et al.
Journal of Forensic Sciences|October 5, 2006
Adult Hirschsprung's disease diagnosed during forensic autopsyDenis Chatelain, Cécile Manaouil, Bernard Marc, et al.
The Lancet. Infectious Diseases|September 7, 2025
A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trialJohn Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, et al.
Journal of the International AIDS Society|February 9, 2025
Early initiation of fast-track care for persons living with HIV initiating dolutegravir-based regimens during a period of severe civil unrest in Port-au-Prince, Haiti: a pilot randomized trialJean Bernard Marc, Samuel Pierre, Othnia Ducatel, et al.
Open Forum Infectious Diseases|July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 SitesCissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Presse Medicale (Paris, France : 1983)|August 1, 2002
[Sexual abuse and chemical submission, a present-day problem]Pascal Burnat, Carine Garcia, Bernard Marc, et al.
Journal of Forensic Sciences|October 5, 2006
Adult Hirschsprung's disease diagnosed during forensic autopsyDenis Chatelain, Cécile Manaouil, Bernard Marc, et al.
The Lancet. Infectious Diseases|September 7, 2025
A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trialJohn Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, et al.
Journal of the International AIDS Society|February 9, 2025
Early initiation of fast-track care for persons living with HIV initiating dolutegravir-based regimens during a period of severe civil unrest in Port-au-Prince, Haiti: a pilot randomized trialJean Bernard Marc, Samuel Pierre, Othnia Ducatel, et al.
Open Forum Infectious Diseases|July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 SitesCissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 2